• Clinical Data
  • Quality Of Life
  • QoL in the ascent trial

TRODELVY 200mg

Clinical Data

TRODELVY demonstrated significant improvements in HRQoL vs chemotherapy1

In an assessment of patient-reported outcomes in the ASCENT trial, TRODELVY demonstrated statistically significant and clinically meaningful improvements vs single-agent chemotherapy in overall scores in all 5 primary HRQoL domains1

QoL in the ascent trial

TRODELVY significantly shortened time to improvement in
physical functioning and pain vs single-agent chemotherapy1

ABBREVIATIONS:

HRQoL, health-related quality of life; mBC, metastatic breast cancer; QoL, quality of life.

REFERENCES:

  1. Loibl S, et al. Ann Oncol. 2021;32(5):S457–S515.